Anzeige
Mehr »
Dienstag, 22.07.2025 - Börsentäglich über 12.000 News
Alarm am Metallmarkt: Kupfer unter Strom: USA rüsten sich - was das für Anleger bedeutet
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40EDR | ISIN: US46489V3024 | Ticker-Symbol: AAJ0
Frankfurt
21.07.25 | 08:06
3,520 Euro
-5,38 % -0,200
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
PERSPECTIVE THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
PERSPECTIVE THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
3,6403,76021.07.
3,6203,76021.07.

Aktuelle News zur PERSPECTIVE THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
PERSPECTIVE THERAPEUTICS Aktie jetzt für 0€ handeln
15.07.Perspective Therapeutics, Inc.: Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2025 Financial Results80SEATTLE, July 15, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers...
► Artikel lesen
03.07.Perspective Therapeutics, Inc. - 8-K, Current Report4
23.06.Perspective Therapeutics, Inc. - 8-K, Current Report3
21.06.Perspective Therapeutics, Inc.: Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2025 Annual Meeting3
21.06.Perspective Therapeutics, Inc.: Perspective Therapeutics Commences Recruitment for [212Pb]VMT-a-NET in the Third Dose Escalation Cohort of its Ongoing Phase 1/2a Clinical Trial61[212Pb]VMT-a-NET Phase 1/2a study is advancing into Cohort 3 with a fixed administered dose that is up to 20% higher (6 mCi) than the dose administered to patients in Cohort 2Dosimetry sub-study analysis...
► Artikel lesen
03.06.RBC Capital raises Perspective Therapeutics stock price target to $167
03.06.RBC Capital erhöht Kursziel für Perspective Therapeutics-Aktie auf 16 US-Dollar5
30.05.Perspective Therapeutics, Inc.: Perspective Therapeutics Highlights Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-a-NET at the 2025 ASCO Annual Meeting192Updated interim results with an additional ~16 weeks of follow-up on nine patients in Cohort 1 (2.5 mCi) and Cohort 2 (5.0 mCi) and initial safety findings in an additional 33 patients treated in...
► Artikel lesen
28.05.Perspective Therapeutics gibt Abstimmungsergebnisse bekannt22
28.05.Perspective Therapeutics, Inc. - 8-K, Current Report1
12.05.Perspective Therapeutics, Inc.: Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2025 Results407First of several clinical updates through mid-2026 accepted for presentation at the 2025 American Society of Clinical Oncology Annual Meeting, with recruitment progressing for all three of our clinical...
► Artikel lesen
12.05.Perspective Therapeutics, Inc. - 10-Q, Quarterly Report5
12.05.Perspective Therapeutics, Inc. - 8-K, Current Report2
11.05.Perspective Therapeutics Q1 2025 Earnings Preview3
29.04.Perspective Therapeutics, Inc. - 8-K, Current Report2
29.04.Perspective Therapeutics, Inc.: Perspective Therapeutics Announces First Patient Dosed with PSV359 in a Phase 1/2a Study in Patients with FAP-a Positive Solid Tumors270SEATTLE, April 29, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for...
► Artikel lesen
23.04.Perspective Therapeutics, Inc.: Perspective Therapeutics Announces Acceptance of VMT-a-NET and VMT01 Data for Presentation at the 2025 ASCO Annual Meeting3
17.04.Perspective Therapeutics, Inc.: Perspective Therapeutics to Provide Business Highlights and Report First Quarter 2025 Financial Results1
11.04.Perspective Therapeutics, Inc. - 8-K, Current Report2
11.04.Perspective Therapeutics, Inc.: Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 Monotherapy at 1.5 mCi in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma179SEATTLE, April 11, 2025 (GLOBE NEWSWIRE) -- Perspective, Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for...
► Artikel lesen
Weiter >>
40 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1